TrialThe Lancet. Respiratory medicine2021

Safety and immunogenicity of CpG 1018 and aluminium hydroxide-adjuvanted SARS-CoV-2 S-2P protein vaccine MVC-COV1901: interim results of a large-scale, double-blind, randomised, placebo-controlled phase 2 trial in Taiwan.

Szu-Min Hsieh et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.